Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945700 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9945705 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9945703 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL17401247 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL8731954 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL17401248 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL42956 | 0.96 | ALDH1A1 (0.48) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL10882313 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL4323031 | 0.93 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| Potassium SCHEMBL2529395 | 0.93 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-25 | — | — | US | disclosed |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9944632-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-9840479-B2 | Polyamine-fatty acid derived lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-12 | — | — | US | disclosed |
| US-9715040-B2 | Optical film and manufacturing method thereof, polarizing plate protective film, polarizing plate and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2017-07-25 | — | — | US | disclosed |
| WO-2017091673-A2 | BIVALENT BROMODOMAIN INHIBTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160047946-A1 | OPTICAL FILM AND MANUFACTURING METHOD THEREOF, POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160002178-A1 | POLYAMINE-FATTY ACID DERIVED LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ESR2, ESRRB, ESRRA | ALDH1A1 2070/4885CA12 2268/4885CA1 3713/4885 |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | ALDH1A1 706/4885CA12 3469/4885CA1 3999/4885 |
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | CDK9, CDK19, CRBN | ALDH1A1 4013/4885CA12 2231/4885CA1 1811/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ALDH1A1 3542/4885CA12 4613/4885CA1 4555/4885 |
| US-20160002178-A1 | POLYAMINE-FATTY ACID DERIVED LIPIDOIDS AND USES THEREOF | SGMS2, SGMS1, ARG2 | ALDH1A1 2532/4885CA12 4831/4885CA1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.